Leptin is an anorexigenic mediator that reduces food intake by acting on hypothalamic receptor Ob-Rb. In contrast, endocannabinoids are orexigenic mediators that act via cannabinoid CB1 receptors in hypothalamus, limbic forebrain, and brainstem. In the peripheral taste system, leptin administration selectively inhibits behavioural, taste nerve and taste cell responses to sweet compounds. Opposing the action of leptin, endocannabinoids enhance sweet taste responses. However, potential roles of endogenous leptin and endocannabinoids in sweet taste remain unclear. Here, we used pharmacological antagonists (Ob-Rb: L39A/D40A/F41A (LA), CB1: AM251) and examined the effects of their blocking activation of endogenous leptin and endocannabinoid signalling on taste responses in lean control, leptin receptor deficient db/db, and diet-induced obese (DIO) mice. Lean mice exhibited significant increases in chorda tympani (CT) nerve responses to sweet compounds after LA administration, while they showed no significant changes in CT responses after AM251. In contrast, db/db mice showed clear suppression of CT responses to sweet compounds after AM251, increased endocannabinoid (2-arachidonoyl-sn-glycerol (2-AG)) levels in the taste organ, and enhanced expression of a biosynthesizing enzyme (diacylglycerol lipase α (DAGLα)) of 2-AG in taste cells. In DIO mice, the LA effect was gradually decreased and the AM251 effect was increased during the course of obesity. Taken together, our results suggest that circulating leptin, but not local endocannabinoids, may be a dominant modulator for sweet taste in lean mice; however, endocannabinoids may become more effective modulators of sweet taste under conditions of deficient leptin signalling, possibly due to increased production of endocannabinoids in taste tissue. Key points Potential roles of endogenous leptin and endocannabinoids in sweet taste were examined by using pharmacological antagonists and mouse models including leptin receptor deficient (db/db) and diet-induced obese (DIO) mice. Chorda tympani (CT) nerve responses of lean mice to sweet compounds were increased after administration of leptin antagonist (LA) but not affected by administration of cannabinoid receptor antagonist (AM251). db/db mice showed clear suppression of CT responses to sweet compounds after AM251, increased endocannabinoid levels in the taste organ, and enhanced expression of a biosynthesizing enzyme of endocannabinoids in taste cells. The effect of LA was gradually decreased and that of AM251 was increased during the course of obesity in DIO mice. These findings suggest that circulating leptin, but not local endocannabinoids, is a dominant modulator for sweet taste in lean mice and endocannabinoids become more effective modulators of sweet taste under conditions of deficient leptin signalling. Introduction Taste is primarily devoted to the selection of foods and required nutrients, and the avoidance of potentially harmful compounds. Sweet sensing is thought to be essential for the detection of carbohydrate sources of calories. Sensory input from sweet sensing cells to the brain may serve as a signal that can provoke palatability of food to stimulate food intake, and facilitate secretion of insulin in the pancreas and other factors in the gut involved in regulating nutrient absorption and energy homeostasis. Recent studies reveal that the peripheral sweet-sensing system is modulated by the anorexigenic mediator leptin (Kawai et al. 2000) and the orexigenic endocannabinoids 2-arachidonoyl-sn-glycerol (2-AG) and anandamide (N-arachidonoylethanolamine (AEA) (Yoshida et al. 2010). Leptin, an adipocyte-derived hormone, primarily acts on functional leptin receptors (Ob-Rb) in the hypothalamus and reduces food intake, increases energy expenditure, and regulates body weight (Friedman & Halaas, 1998; Friedman 2004). The db/db mice have a point mutation of the db gene, lack functional leptin receptors, and are hyperphagic, massively obese and diabetic (Lee et al. 1996). In the peripheral taste system, taste cells express Ob-Rb and administration of recombinant leptin selectively suppresses taste cell, taste nerve and behavioural responses to sweet compounds without affecting responses to other basic taste stimuli (salty, sour, bitter and umami compounds) in lean control mice (Kawai et al. 2000; Shigemura et al. 2004; Yoshida et al. 2013). The db/db mice show no such leptin inhibition on sweet taste responses, but instead exhibit greater gustatory neural sensitivities (Ninomiya et al. 1995, 1998; Sako et al. 1996) and higher behavioural preferences (Ninomiya et al. 1995) for various sweet compounds compared with lean control mice. Endocannabinoids act on cannabinoid receptor 1 (CB1 receptor) in the hypothalamus and limbic forebrain to induce appetite (Jamshidi & Taylor, 2001; Cota et al. 2003) and stimulate food intake, which opposes the action of leptin. Systemic administration of exogenous cannabinoids and endocannabinoids in rodents causes hyperphagia (Williams & Kirkham, 1999) and increases the preference for palatable substances, such as sucrose solution and sweetened food pellets (Higgs et al. 2003; Jarrett et al. 2005). Infusions of 2-AG into the pontine parabrachial nucleus, which contains third order gustatory neurons, increase intake of palatable foods, including sucrose pellets, without affecting the intake of normal chow (DiPatrizio & Simansky, 2008), suggesting that endocannabinoids may be related to hedonic aspects of sweet taste. In the peripheral taste system, comparable with their central action, systemic administration of 2-AG or AEA selectively increased taste cell, nerve and behavioural responses to sweeteners without affecting responses to salty, sour, bitter and umami compounds (Yoshida et al. 2010). Mice genetically lacking CB1 receptors showed no such enhancement of sweet taste responses by endocannabinoids and the sweet-enhancing effect was prevented by a CB1 antagonist (Yoshida et al. 2010), indicating that the effect may be mediated by CB1 receptors. Reciprocal regulation of peripheral sweet taste reception by endocannabinoids and leptin may, thus, contribute to their opposing actions on food intake and energy homeostasis. In our previous studies (Kawai et al. 2000; Yoshida et al. 2010), however, reciprocal modulation of sweet taste responses by leptin and endocannabinoids was found only in separate experiments after systemic administration of exogenous leptin and endocannabinoids to mice. Therefore, it remains unclear to what extent endogenous leptin or endocannabinoids tonically affect peripheral taste responsiveness in mice. In the hypothalamus, leptin inhibits production of endocannabinoids (Jo et al. 2005). Conversely, hypothalamic endocannabinoids are increased in genetically obese rodents lacking functional leptin (ob/ob mice) and leptin receptors (db/db mice and Zucker rats; Di Marzo et al. 2001). These studies suggest that endocannabinoids are normally under negative control by leptin, and might be involved in the hyperphagia and obesity that accompany defects in leptin signalling. A potential site for the interaction between leptin and endocannabinoids is reported in lateral hypothalamic neurons, where leptin inhibits voltage-gated calcium channels, preventing the influx of calcium into cells and blocking endocannabinoid release and synthesis (Jo et al. 2005), a mechanism that contributes to the appetite-suppressing effect of leptin. This evidence raises the possibility that such interaction between leptin and endocannabinds could also be involved in modulation of sweet responsiveness of taste cells and the sweet taste modulator could be switched from leptin in lean mice to endocannabinoid in obese mice with defects in leptin signalling. To answer these questions, we first investigated the effects of pharmacological inhibition of leptin or endocannabinoid receptors on peripheral taste responses in lean control mice with and without food deprivation, and in db/db mice. We treated mice with a leptin receptor antagonist, the leptin triple mutant L39A/D40A/F41A (LA), which is reported to increase food intake of normal chow-fed rats when infused into the lateral ventricle (Zhang et al. 2007), and the CB1 antagonist AM251, which is shown following systemic administration in mice to decrease the intake of a high-fat diet (Hildebrandt et al. 2003). Furthermore, we investigated the molecular basis for endocannabinoid actions on the taste organ. Finally, we investigated a proposed switch of the sweet taste modulator from leptin to endocannabinoids by comparing LA and AM251 effects on sweet taste responses at different stages of development of diet-induced obese (DIO) mice.